These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3904040)

  • 1. Comparative bio-availability of four formulations of furosemide.
    Meyer BH; Müller FO; Swart KJ; Luus HG; Werkman IM
    S Afr Med J; 1985 Oct; 68(9):645-7. PubMed ID: 3904040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penbutolol and furosemide in a fixed-dose combination-bio-equivalence of two formulations.
    Meyer BH; Müller FO; Hundt HK; Grigoleit HG; Hajdu P; Heptner W
    S Afr Med J; 1981 Jun; 59(25):891-3. PubMed ID: 7015536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bioequivalence study of two products of furosemide tablets.
    Awad R; Arafat T; Saket M; Saleh M; Gharaibeh M; Zmeili S; Sallam E; Shubair M; Qobrosi S
    Int J Clin Pharmacol Ther Toxicol; 1992 Jan; 30(1):18-23. PubMed ID: 1551740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers.
    Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
    Biopharm Drug Dispos; 2003 Sep; 24(6):245-9. PubMed ID: 12973821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of intraindividual variability in bioavailability studies of furosemide.
    Grahnén A; Hammarlund M; Lundqvist T
    Eur J Clin Pharmacol; 1984; 27(5):595-602. PubMed ID: 6519165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bio-availability of three formulations of glibenclamide.
    Meyer BH; Müller FO; Luus HG; Eckert HG
    S Afr Med J; 1989 Aug; 76(4):146-7. PubMed ID: 2503895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desorption of furosemide from charcoal in vitro and in man.
    Roivas L; Kivistö KT; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):365-9. PubMed ID: 7952799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations.
    Cuadrado A; Rodríguez Gascón A; Hernández RM; Castilla AM; de la Maza A; Yánez C; López de Ocáriz A; Solinís MA; Pedraz JL
    Arzneimittelforschung; 2003; 53(5):321-9. PubMed ID: 12854359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic and pharmacokinetic study of a slow-release formulation of furosemide in man.
    Ebihara A; Tawara K; Oka T
    Arzneimittelforschung; 1983; 33(1):163-6. PubMed ID: 6681970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bioavailability of two furosemide formulations in humans.
    Martin BK; Uihlein M; Ings RM; Stevens LA; McEwen J
    J Pharm Sci; 1984 Apr; 73(4):437-41. PubMed ID: 6726624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study.
    Suthisisang C; Payakachat N; Chulavatnatol S; Towanabut S
    J Med Assoc Thai; 1998 Jan; 81(1):64-70. PubMed ID: 9470324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable furosemide absorption and poor predictability of response in elderly patients.
    Murray MD; Haag KM; Black PK; Hall SD; Brater DC
    Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum.
    Lee WI; Yoon WH; Shin WG; Song IS; Lee MG
    Biopharm Drug Dispos; 1997 Dec; 18(9):753-67. PubMed ID: 9429740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bio-availability of theophylline whole and halved sustained-release tablets.
    Müller FO; Hundt HK; Luus HG; van Dyk M; Groenewoud G; van der Meer MJ; Steinijans VW
    S Afr Med J; 1987 Aug; 72(3):175-8. PubMed ID: 3299763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrimination between five oral frusemide preparations using renal chloride excretion and frusemide recovery.
    Eggers NJ; Kingsford M; Saint Joly CM; Jellett LB; Shirkey RJ
    N Z Med J; 1983 Nov; 96(744):963-6. PubMed ID: 6355931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin bio-availability. A comparison of 4 products.
    Müller FO; Steyn JM; Hundt HK; Luus HG
    S Afr Med J; 1988 Dec; 74(11):566-7. PubMed ID: 3057655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmaceutical and biological availability of commercial preparations of furosemide.
    Stüber W; Mutschler E; Steinbach D
    Arzneimittelforschung; 1982; 32(6):693-7. PubMed ID: 6889429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of two preparations of frusemide.
    Paton DM
    N Z Med J; 1980 Mar; 91(656):208-10. PubMed ID: 6929997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers.
    Setiawati E; Yunaidi DA; Handayani LR; Santoso ID; Setiawati A; Tjandrawinata RR
    Arzneimittelforschung; 2011; 61(12):681-4. PubMed ID: 22282954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.